Comparative Pharmacology
Head-to-head clinical analysis: DIFLUCAN IN DEXTROSE 5 IN PLASTIC CONTAINER versus ECONAZOLE NITRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIFLUCAN IN DEXTROSE 5 IN PLASTIC CONTAINER versus ECONAZOLE NITRATE.
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER vs ECONAZOLE NITRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diflucan (fluconazole) inhibits fungal cytochrome P450 14α-demethylase (CYP51), blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This disrupts membrane integrity and function, leading to fungal cell death. At high concentrations, it may also directly damage fungal membranes.
Econazole nitrate, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase (CYP51), blocking ergosterol synthesis, disrupting fungal cell membrane integrity and function.
200 mg IV loading dose, then 100-200 mg IV once daily; for invasive candidiasis, 800 mg IV loading dose then 400 mg IV once daily.
Topical: Apply a thin layer to affected area twice daily (morning and evening). Vaginal: One applicatorful (150 mg) intravaginally at bedtime for 3 days. Rectal candidiasis: One 150 mg suppository rectally at bedtime for 3 days.
None Documented
None Documented
Terminal elimination half-life is approximately 30 hours (range 20-50 hours) in adults with normal renal function; prolonged to 98 hours in end-stage renal disease, requiring dose adjustment.
Terminal elimination half-life approximately 8-10 hours; clinical relevance: supports twice-daily topical dosing for sustained antifungal effect.
Approximately 80% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion; about 11% is excreted as metabolites in urine; fecal excretion accounts for less than 5%.
Primarily hepatic metabolism; <1% unchanged in urine; 30-45% in feces as metabolites; minimal biliary excretion.
Category C
Category A/B
Antifungal
Antifungal